These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22933706)

  • 1. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
    Jones RJ; Bjorklund CC; Baladandayuthapani V; Kuhn DJ; Orlowski RZ
    Mol Cancer Ther; 2012 Oct; 11(10):2243-53. PubMed ID: 22933706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
    Michaelis M; Rothweiler F; Agha B; Barth S; Voges Y; Löschmann N; von Deimling A; Breitling R; Doerr HW; Rödel F; Speidel D; Cinatl J
    Cell Death Dis; 2012 Apr; 3(4):e294. PubMed ID: 22476102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
    Jones RJ; Chen Q; Voorhees PM; Young KH; Bruey-Sedano N; Yang D; Orlowski RZ
    Clin Cancer Res; 2008 Sep; 14(17):5416-25. PubMed ID: 18765533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
    Tabe Y; Sebasigari D; Jin L; Rudelius M; Davies-Hill T; Miyake K; Miida T; Pittaluga S; Raffeld M
    Clin Cancer Res; 2009 Feb; 15(3):933-42. PubMed ID: 19188164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
    Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
    Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
    Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
    Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.
    Aziz MH; Shen H; Maki CG
    Oncogene; 2011 Nov; 30(46):4678-86. PubMed ID: 21643018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.
    Gu D; Wang S; Kuiatse I; Wang H; He J; Dai Y; Jones RJ; Bjorklund CC; Yang J; Grant S; Orlowski RZ
    PLoS One; 2014; 9(9):e103015. PubMed ID: 25181509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.
    Cheok CF; Kua N; Kaldis P; Lane DP
    Cell Death Differ; 2010 Sep; 17(9):1486-500. PubMed ID: 20203688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
    Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
    Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.
    Saha MN; Jiang H; Mukai A; Chang H
    Mol Cancer Ther; 2010 Nov; 9(11):3041-51. PubMed ID: 21062913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.
    Kurokawa M; Kim J; Geradts J; Matsuura K; Liu L; Ran X; Xia W; Ribar TJ; Henao R; Dewhirst MW; Kim WJ; Lucas JE; Wang S; Spector NL; Kornbluth S
    Sci Signal; 2013 May; 6(274):ra32. PubMed ID: 23652204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
    Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
    Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
    Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
    Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN; Jiang H; Chang H
    Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
    Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
    PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.